cPLA2alpha, COX-2 and TGF-beta in Liver Cancer
cPLA2α、COX-2 和 TGF-β 在肝癌中的作用
基本信息
- 批准号:7653585
- 负责人:
- 金额:$ 10.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-07-15 至 2010-12-31
- 项目状态:已结题
- 来源:
- 关键词:ActinsAnimalsApoptosisArachidonic AcidsCancer Cell GrowthCancerousCarbon TetrachlorideCell ProliferationCellsChemopreventionChronicChronic HepatitisCirrhosisClassificationCoculture TechniquesCytosolic Phospholipase A2DataDevelopmentDiethylnitrosamineDinoprostoneEMSAElectrophoretic Mobility Shift AssayEmbryoEnzymesEpithelial CellsExperimental Animal ModelExtracellular MatrixGenetic TranscriptionGlial Fibrillary Acidic ProteinGrantGrowthHepaticHepatic FibrogenesisHepatic Stellate CellHepatocarcinogenesisHepatocyteHumanIn VitroIncidenceInflammationInflammatoryKnock-outKnockout MiceLaboratoriesLinkLipoxygenaseLiverLiver FibrosisLiver RegenerationLiver diseasesLiver neoplasmsMAP Kinase GeneMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of liverMediatingMetabolismMusMuscleNeoplastic Epithelial CellNon-Steroidal Anti-Inflammatory AgentsPartial HepatectomyPathogenesisPathway interactionsPeroxisome Proliferator-Activated ReceptorsPhospholipasePhospholipase A2PhosphorylationPlayPredispositionPrimary carcinoma of the liver cellsProcessProductionProstaglandin-Endoperoxide SynthaseProstaglandinsProtein KinasePublishingResistanceResponse ElementsRoleSCID MiceSeriesSevere Combined ImmunodeficiencySignal PathwaySignal TransductionSmall Interfering RNATherapeuticTherapeutic InterventionTissuesTransforming Growth Factor betaTransforming Growth FactorsTransgenic MiceTransgenic OrganismsUnited StatesWild Type Mousebasecancer cellcarcinogenesiscell growthcyclooxygenase 2cytokineexpectationfodrinin vivoliver cell proliferationmortalityneoplastic cellnoveloverexpressionpreventpublic health relevancereceptorresearch studyresponsetransdifferentiationtumortumor growthtumor progression
项目摘要
DESCRIPTION (provided by applicant): Primary liver cancer is the common malignant neoplasm in human with high mortality and its incidence is rising worldwide, especially in the United States. It occurs largely in the preexisting chronic inflammatory liver disorders, including chronic hepatitis and cirrhosis. Recent studies from our lab show that prostaglandin (PG) metabolism plays an important role in liver inflammation and carcinogenesis. In this grant we hypothesize that the level and activation status of prostaglandin signaling represents a key factor that determines the cellular response to transforming growth factor-? (TGF-?). Specifically, we postulate that enhanced cytosolic phospholipase A2? (cPLA2?) and cyclooxygenase-2 (COX-2) controlled PG signaling subverts TGF-?-mediated mitoinhibition and this mechanism is critically involved in liver carcinogenesis through selection and expansion of TGF-? resistant dysplastic and neoplastic epithelial cells that progress more rapidly toward malignant transformation and tumor development. Therefore, blocking PG signaling may restore the growth- inhibitory action of TGF-??and prevent hepatocarcinogenesis. This application proposes a series of experiments to evaluate the above hypotheses. Human liver cancer cells with altered expression of cPLA2? and COX-2 will be utilized to determine their response to TGF-?. siRNA for Smad2/3 will be introduced into human liver cancer cells stably expressing antisense cPLA2? or COX-2 and these cells will be analyzed for proliferation and apoptosis, in vitro and in SCID mice. Transgenic mice with targeted expression of cPLA2? and COX- 2 in the liver will be developed and utilized to determine TGF-?-regulated Smad activation, mitoinhibition, apoptosis, and hepatocarcinogenesis. The cPLA2? and COX-2 transgenic and knockout mice will be crossed with the TGF-?receptor type II knockout mice to determine liver regeneration and DEN-induced hepatocarcinogenesis. Finally, cultured hepatic stellate cells and experimental animal models will be utilized to evaluate our hypothesis that TGF-? and PG signaling in the fibrogenic hepatic stellate cells is critically involved in the pathogenesis of liver fibrosis and carcinogenesis. Results from the proposed studies are expected to provide important therapeutic implications for the chemoprevention and treatment of human liver cancer. PUBLIC HEALTH RELEVANCE: Primary liver cancer is a highly malignant neoplasm in human and currently there is no effective chemoprevention or systematic therapy. This application is proposed to examine our hypothesis that the level and activation status of prostaglandin signaling represents a key factor that determines the cellular response to TGF-? and that blocking prostaglandin signaling may restore the growth-inhibitory action of TGF-? and prevent hepatocarcinogenesis. A series of experiments will be performed to evaluate this central hypothesis. Results of the proposed experiments are expected to reveal an important link between TGF-? and prostaglandin signaling pathways in liver carcinogenesis and provide important therapeutic implications.
描述(由申请人提供):原发性肝癌是死亡率高的人类中常见的恶性肿瘤,其发病率在全球范围内上升,尤其是在美国。它主要发生在早期存在的慢性炎性肝疾病中,包括慢性肝炎和肝硬化。我们实验室的最新研究表明,前列腺素(PG)代谢在肝脏炎症和致癌作用中起着重要作用。在这笔赠款中,我们假设前列腺素信号的水平和激活状态代表了决定细胞对转化生长因子的反应的关键因素。 (TGF-?)。具体而言,我们假设增强了胞质磷脂酶A2? (CPLA2?)和环氧合酶-2(COX-2)受控的PG信号传导颠覆TGF - ?? - 通过选择和扩展TGF-的介导的有丝氨酸抑制作用,这种机制与肝癌发生了严重涉及?耐药性发育不良和肿瘤上皮细胞更快地朝着恶性转化和肿瘤发育发展。因此,阻断PG信号传导可能会恢复TGF的生长抑制作用,并防止肝癌发生。该应用程序提出了一系列评估上述假设的实验。人肝癌细胞的CPLA2表达改变了?将使用COX-2来确定它们对TGF-?的响应。 SMAD2/3的siRNA将被引入稳定表达反义CPLA2的人肝癌细胞中?或COX-2和这些细胞将在体外和SCID小鼠中分析增殖和凋亡。转基因小鼠具有CPLA2的靶向表达?将开发并利用肝脏中的Cox-2来确定TGF - ? - 调节的Smad激活,线抑制,凋亡和肝癌发生。 CPLA2? COX-2转基因和基因敲除小鼠将与TGF-?受体II型敲除小鼠交叉,以确定肝脏再生和DEN诱导的肝癌发生。最后,将利用培养的肝星状细胞和实验动物模型来评估我们的TGF-的假设?纤维化肝星状细胞中的PG信号传导与肝纤维化和癌变的发病机理至关重要。拟议研究的结果预计将为人肝癌的化学预防和治疗提供重要的治疗意义。公共卫生相关性:原发性肝癌是人类高度恶性的肿瘤,目前尚无有效的化学预防或系统治疗。提出了该应用程序来检验我们的假设,即前列腺素信号的水平和激活状态代表了决定细胞对TGF-的反应的关键因素?阻止前列腺素信号传导可能会恢复TGF-的抑制作用作用?并防止肝癌发生。将进行一系列实验以评估这一中心假设。提出的实验的结果有望揭示TGF-之间的重要联系?肝癌发生中的前列腺素信号通路,并提供重要的治疗意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tong Wu其他文献
Tong Wu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tong Wu', 18)}}的其他基金
Epigenetic Mechanisms of Biliary Epithelial Neoplasia
胆管上皮肿瘤的表观遗传机制
- 批准号:
10430173 - 财政年份:2018
- 资助金额:
$ 10.9万 - 项目类别:
Epigenetic Mechanisms of Biliary Epithelial Neoplasia
胆管上皮肿瘤的表观遗传机制
- 批准号:
10626746 - 财政年份:2018
- 资助金额:
$ 10.9万 - 项目类别:
The Long Noncoding RNA MALAT1 in Liver Cancer
肝癌中的长非编码 RNA MALAT1
- 批准号:
10542840 - 财政年份:2018
- 资助金额:
$ 10.9万 - 项目类别:
The Long Noncoding RNA MALAT1 in Liver Cancer
肝癌中的长非编码 RNA MALAT1
- 批准号:
10062895 - 财政年份:2018
- 资助金额:
$ 10.9万 - 项目类别:
The Long Noncoding RNA MALAT1 in Liver Cancer
肝癌中的长非编码 RNA MALAT1
- 批准号:
10304936 - 财政年份:2018
- 资助金额:
$ 10.9万 - 项目类别:
Epigenetic Mechanisms of Biliary Epithelial Neoplasia
胆管上皮肿瘤的表观遗传机制
- 批准号:
10196993 - 财政年份:2018
- 资助金额:
$ 10.9万 - 项目类别:
Omega-3 Fatty Acids and Hepatic Carcinogenesis
Omega-3 脂肪酸与肝癌发生
- 批准号:
8214608 - 财政年份:2010
- 资助金额:
$ 10.9万 - 项目类别:
Omega-3 Fatty Acids and Hepatic Carcinogenesis
Omega-3 脂肪酸与肝癌发生
- 批准号:
8449722 - 财政年份:2010
- 资助金额:
$ 10.9万 - 项目类别:
Omega-3 Fatty Acids and Hepatic Carcinogenesis
Omega-3 脂肪酸与肝癌发生
- 批准号:
8096663 - 财政年份:2010
- 资助金额:
$ 10.9万 - 项目类别:
相似国自然基金
丁苯酞通过调节细胞异常自噬和凋亡来延缓脊髓性肌萎缩症动物模型脊髓运动神经元的丢失
- 批准号:82360332
- 批准年份:2023
- 资助金额:31.00 万元
- 项目类别:地区科学基金项目
利用可视可控hypocretin神经元凋亡的疾病模型进行发作性睡病发病机制研究
- 批准号:81901346
- 批准年份:2019
- 资助金额:20.5 万元
- 项目类别:青年科学基金项目
组织器官衰老致退行性演变多示踪剂全身动态PET显像研究
- 批准号:91949121
- 批准年份:2019
- 资助金额:68.0 万元
- 项目类别:重大研究计划
日粮AFB1在反刍动物肝脏中代谢激活和诱导肝细胞凋亡的分子机理研究
- 批准号:31902187
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
阿司匹林丁香酚酯抗氧化应激致血管内皮细胞凋亡的分子机制
- 批准号:31872518
- 批准年份:2018
- 资助金额:59.0 万元
- 项目类别:面上项目
相似海外基金
Evaluating the efficacy of Butyric acid pro-drug nanoparticle in retinal neuroprotection
评估丁酸前药纳米颗粒在视网膜神经保护中的功效
- 批准号:
10602346 - 财政年份:2023
- 资助金额:
$ 10.9万 - 项目类别:
Unanticipated roles of C5aR1 Signaling Leading from Acute to Chronic Kidney Disease
C5aR1 信号转导从急性肾病到慢性肾病的意外作用
- 批准号:
10591053 - 财政年份:2023
- 资助金额:
$ 10.9万 - 项目类别:
Integrin αvβ3 preclinical PET imaging to detect early stage NASH and treatment response
整合素αvβ3 临床前 PET 成像检测早期 NASH 和治疗反应
- 批准号:
10630367 - 财政年份:2022
- 资助金额:
$ 10.9万 - 项目类别:
Innovating Organ Shipment by Studying Environmental Factors which Affect Organs During Cold Preservation
研究冷藏过程中影响器官的环境因素,创新器官运输
- 批准号:
10689394 - 财政年份:2022
- 资助金额:
$ 10.9万 - 项目类别:
Targeting beta1 integrin in JAK2V617F+ stem cells
靶向 JAK2V617F 干细胞中的 β1 整合素
- 批准号:
10575092 - 财政年份:2022
- 资助金额:
$ 10.9万 - 项目类别: